Amylyx Pharmaceuticals Stock News

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders.

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis.

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences.

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Lindsey Allen - Vice President Investor Relations and Communications Justin Klee - Co-CEO Camille Bedrosian - Chief Medical Officer Jim Frates - Chief Financial Officer Josh Cohen - Co-CEO Conference Call Participants Michael DiFiore - Evercore ISI Marc Goodman - Leerink Tim ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals reports First Quarter 2025 financial results.

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences.

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025.